Aurigene Announces First Patient Dosed with AUR101 in Phase II Study in Patients with Moderate to Severe Psoriasis

PRESS RELEASE Aurigene Announces First Patient Dosed with AUR101 in Phase II Study in Patients with Moderate to Severe Psoriasis   Bangalore, February 17, 2020 — Aurigene, a development stage

Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170

PRESS RELEASE Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170 – Aurigene to fund and conduct a Phase 2b/3 randomized study of CA-170 in

Exelixis and Aurigene Enter Into Exclusive Collaboration, Option and License Agreement to Discover and Develop Novel Therapies for Cancer

ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into an exclusive collaboration, option and license agreement with Aurigene Discovery Technologies Limited (Aurigene), the India-based discovery biotechnology

Aurigene Announces First in Human Dosing with RoRγt inverse agonist AUR-101

– Phase 1 data from the study expected to be available by December 2018   Aurigene, a biotechnology company focused on discovering and developing drugs for oncology and inflammatory disorders,

Aurigene and its Partner Curis Announce the dosing of CA-170 in Phase II India trial

The Phase 2 trial is the result of the initial safety data and preliminary evidence of clinical benefit observed in the trial. Aurigene Discovery Technologies Limited, a wholly owned subsidiary

Aurigene, a wholly owned subsidiary of Dr Reddy’s, and Curis announce CA-170 program update following data presented at ESMO 2017

Aurigene, a wholly owned subsidiary of Dr Reddy’s, and Curis announce CA-170 program update following data presented at ESMO 2017 — Results from 34 patients demonstrate positive safety profile and